NCT04818255

STIM+: PET Biomarker Education & Disclosure

Stimulation to Improve Memory: PET Education & Disclosure

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 152 (actual)
• Sponsor: University of Michigan · Academic / Other
• Sex: All
• Age: 55 Years
• Healthy volunteers: Not accepted

Summary

When dementia is caused by AD, we refer to it as dementia of the Alzheimer's Type (DAT). The greatest risk factor for Alzheimer's Disease (AD) and DAT is advancing age, but DAT is not a normal part of aging. Studies have shown that changes in the brain happen before full symptoms of DAT develop. These changes include a buildup of two proteins within the brain, called amyloid and tau. The two goals of this study are (1) to determine whether patients with mild cognitive impairment or dementia-Alzheimer's type (DAT) are able to demonstrate decisional capacity to engage in PET amyloid and tau disclosure after receiving education; and (2) to assess how patients and care partners react to PET amyloid and tau biomarker disclosure.

Conditions

• Mild Cognitive Impairment
• Dementia; Alzheimer's Type (Etiology)

Interventions

Type	Name	Description
BEHAVIORAL	PET Biomarker Disclosure	Participants receive information about whether they currently have elevated or not-elevated amyloid and/or tau based on recent PET imaging conducted as part of an affiliated research study (no additional imaging is required for this project). Participants meet with a licensed clinical neuropsychologist to discuss their biomarker status, the meaning of this information, and potential next steps to consider based of their status. Participants receive written summaries of this information, as well as resources as deemed necessary or as requested.

Timeline

• Start date: 2020-12-10
• Primary completion: 2024-11-07
• Completion: 2024-11-07
• First posted: 2021-03-26
• Last updated: 2026-01-29
• Results posted: 2026-01-29

Locations

1 site across 1 country: United States